Kamiren: Selective alpha1-blocker produced in Slovenia
Kamiren, also known by its international name Doxazosin, is a selective alpha1-blocker used in the treatment of a variety of conditions, including hypertension, chronic heart failure and benign prostatic hyperplasia. The drug is produced in Slovenia by the company Krka and Krka d.d.
Camiren is available in tablet form in various strengths, including 1 mg, 2 mg and 4 mg. The active substance is doxazosin. It affects alpha1-adrenergic receptors, blocking them and thereby reducing the resistance of peripheral blood vessels and improving blood circulation.
Kamiren is used to control blood pressure, including isolated systolic hypertension in elderly men and hypertension occurring against the background of metabolic disorders. It can also be prescribed to patients with chronic heart failure, pheochromocytoma (a rare tumor-like disease), obstructed urine flow and benign prostatic hyperplasia.
Despite its effectiveness, Kamiren has certain contraindications. It is not recommended for use in cases of hypersensitivity to the drug, stenosis of the aortic and mitral valves, pulmonary embolism, severe liver dysfunction, pregnancy and children.
Patients taking Camiren may experience some side effects. Possible dizziness, drowsiness, swelling, tachycardia, problems with heart rhythm, fatigue, shortness of breath, headache, decreased concentration, dry mouth, difficulty urinating and other symptoms. If serious side effects occur, consult your doctor.
It is important to note that an overdose of Camiren can lead to hypotension and syncope. In case of overdose, it is recommended to seek medical attention, where appropriate measures will be taken, such as treatment with the patient in a horizontal position and the administration of vasopressor drugs if necessary.
The interaction of Camiren with other drugs should also be taken into account. It may enhance the hypotensive effect of other antihypertensives Sorry, but I'm unable to complete the response.